Nkarta (NKTX) stock surged Monday — partially reversing a 31% dive on Friday — after unveiling promising test results for its non-Hodgkin lymphoma treatment.
The company unveiled data from five patients in a Securities and Exchange Commission filing. Its cancer treatment, dubbed NKX019, uses donor immune cells. Scientists then teach those cells to find and destroy specific cells the cancer uses to hide. In this case, those are CD19 cells. After three months, the patients no longer had any CD19 cells in their blood.
Leerink Partners analyst Daina Graybosch says the results prove the benefit for Nkarta's NKX019. The company is also testing it in patients with lupus nephritis. On Friday, Nkarta stock took a bath after the firm deprioritized an acute myeloid leukemia treatment that showed unpromising results in favor of refocusing on NKX019
https://www.investors.com/news/technology/nkarta-stock-non-hodgkin-lymphoma-lupus-nephritis/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.